Core Laboratories N.V. (CLB): Price and Financial Metrics
Core Laboratories N.V. (CLB)
Today's Latest Price: $10.82 USD
Updated Apr 8 3:11pm
Add CLB to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 60 in Energy - Services
See all "A" rated Strong Buy stocks
CLB Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for CLB is 3.76 -- better than 86.86% of US stocks.
- CLB's current price/earnings ratio is 4.75, which is higher than just 12.74% of US stocks with positive earnings.
- In terms of volatility of its share price, CLB is more volatile than 87.07% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Core Laboratories N V, a group of peers worth examining would be FSV, MARA, GHSI, PAGS, and RYB.
- Visit CLB's SEC page to see the company's official filings. To visit the company's web site, go to www.corelab.com.
CLB Stock Price Chart More Charts
CLB Price/Volume Stats
| Current price | $10.82 | 52-week high | $75.63 |
| Prev. close | $10.45 | 52-week low | $6.68 |
| Day low | $10.02 | Volume | 726,093 |
| Day high | $10.94 | Avg. volume | 1,442,227 |
| 50-day MA | $21.71 | Dividend yield | 9.57% |
| 200-day MA | $39.25 | Market Cap | 480.88M |
Core Laboratories N.V. (CLB) Company Bio
Core Laboratories provides proprietary and patented reservoir description, production enhancement, and reservoir management services used to optimize petroleum reservoir performance. The company was founded in 1936 and is based in Amsterdam, the Netherlands.
CLB Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $10.82 | $5.54 | -47% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Core Laboratories N V. To summarize, we found that Core Laboratories N V ranked in the 26th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Core Laboratories N V, consider:
- The company's compound free cash flow growth rate over the past 5.55 years comes in at -0.21%; that's greater than just 9.04% of US stocks we're applying DCF forecasting to.
- Core Laboratories N V's weighted average cost of capital (WACC) is 6%; for context, that number is higher than just 8.75% of tickers in our DCF set.
- The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than merely 19.04% of stocks in its sector (Energy).
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -48% |
| 1% | -48% |
| 2% | -47% |
| 3% | -46% |
| 4% | -46% |
| 5% | -45% |
EGY, PBA, RDS.A, VVV, and ENSV can be thought of as valuation peers to CLB, in the sense that they are in the Energy sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...